Other
11 Authors
- Tian H,
- Phung V,
- Ling L,
- Ko B,
- Zhou M,
- To C,
- Lindhout DA,
- DePaoli AM,
- Luo J,
- Elliott M,
- Learned RM
| First Author | Luo J | Year | 2014 |
| Journal | Sci Transl Med | Volume | 6 |
| Issue | 247 | Pages | 247ra100 |
| PubMed ID | 25080475 | Mgi Jnum | J:215780 |
| Mgi Id | MGI:5606240 | Doi | 10.1126/scitranslmed.3009098 |
| Citation | Luo J, et al. (2014) A nontumorigenic variant of FGF19 treats cholestatic liver diseases. Sci Transl Med 6(247):247ra100 |
| abstractText | Hepatic accumulation of bile acids is central to the pathogenesis of cholestatic liver diseases. Endocrine hormone fibroblast growth factor 19 (FGF19) may reduce hepatic bile acid levels through modulation of bile acid synthesis and prevent subsequent liver damage. However, FGF19 has also been implicated in hepatocellular carcinogenesis, and consequently, the potential risk from prolonged exposure to supraphysiological levels of the hormone represents a major hurdle for developing an FGF19-based therapy. We describe a nontumorigenic FGF19 variant, M70, which regulates bile acid metabolism and, through inhibition of bile acid synthesis and reduction of excess hepatic bile acid accumulation, protects mice from liver injury induced by either extrahepatic or intrahepatic cholestasis. Administration of M70 in healthy human volunteers potently reduces serum levels of 7alpha-hydroxy-4-cholesten-3-one, a surrogate marker for the hepatic activity of cholesterol 7alpha-hydroxylase (CYP7A1), the enzyme responsible for catalyzing the first and rate-limiting step in the classical bile acid synthetic pathway. This study provides direct evidence for the regulation of bile acid metabolism by FGF19 pathway in humans. On the basis of these results, the development of nontumorigenic FGF19 variants capable of modulating CYP7A1 expression represents an effective approach for the prevention and treatment of cholestatic liver diseases as well as potentially for other disorders associated with bile acid dysregulation. |
